Clinical Trials · NCT00715624

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Name: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lixisenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 496
Start date: Jul 2008
Locations: 15 sites, 15 countries
Primary endpoint: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

View Lixisenatide compound reference